摘要
体内和体外研究显示凝溶胶蛋白是一个抵抗淀粉样蛋白。曲古抑菌素A(TSA),是一个组蛋白去乙酰化酶抑制剂,促进凝溶胶蛋白的表达。纤维化的淀粉样蛋白(Aβ)是AD患者脑中淀粉斑块的核心成分。我们研究了TSA对凝溶胶蛋白的水平,淀粉样前蛋白(APP)、蛋白水解酶(γ-分泌酶和β-分泌酶)是Aβ产生的主要原因;Aβ清除酶,即脑啡肽酶(NEP)和胰岛素降解酶(IDE);淀粉样蛋白负载的双转基因(Tg)APPswe/PS1δE9 AD大鼠模型。腹腔内注射TSA2个月(9-11月年龄)导致HDAC活性的降低,与未经处理的大鼠相比, AD Tg大鼠模型的海马和大脑皮层凝溶胶蛋白的水平增长了,TSA同样增加了脑中γ-分泌酶和β-分泌酶的活性水平。但是,TSA对 NEP和IDE在脑中的活性或者表达水平显示任何的效果。此外,TSA治疗的AD Tg大鼠海马区和大脑皮层上淀粉样蛋白的负载没有任何变化(淀粉样蛋白斑块出现的检测区域的比例),这说明TSA治疗并不能导致淀粉样蛋白的负载的降低。有趣的是,TSA能够阻止新的淀粉样蛋白的沉积但是了已有斑块的面积。TSA治疗没有导致脑中任何的凋亡。这些结果说明,TSA增加了凝溶胶蛋白在脑中的表达,TSA的多向性作用减低了凝溶胶蛋白在AD Tg 大鼠中的抗-淀粉样蛋白沉积作用。
关键词: 阿尔茨海默病,淀粉样蛋白斑块,凝溶胶蛋白,组蛋白去乙酰化酶,胰岛素降解酶,脑啡肽酶,分泌酶,转基因大鼠,曲古抑菌素A
Current Alzheimer Research
Title:Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease
Volume: 11 Issue: 10
Author(s): Wenzhong Yang, Abha Chauhan, Jerzy Wegiel, Izabela Kuchna, Feng Gu and Ved Chauhan
Affiliation:
关键词: 阿尔茨海默病,淀粉样蛋白斑块,凝溶胶蛋白,组蛋白去乙酰化酶,胰岛素降解酶,脑啡肽酶,分泌酶,转基因大鼠,曲古抑菌素A
摘要: In vivo and in vitro studies have shown that gelsolin is an anti-amyloidogenic protein. Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, promotes the expression of gelsolin. Fibrillized amyoid beta-protein (Aβ) is a key constituent of amyloid plaques in the brains of patients with Alzheimer’s disease (AD). We studied the effects of TSA on the levels of gelsolin; amyloid precursor protein (APP); proteolytic enzymes (γ-secretase and β-secretase) responsible for the production of Aβ; Aβ-cleaving enzymes, i.e., neprilysin (NEP) and insulin-degrading enzyme (IDE); and amyloid load in the double transgenic (Tg) APPswe/PS1δE9 mouse model of AD. Intraperitoneal injection of TSA for two months (9–11 months of age) resulted in decreased activity of HDAC, and increased levels of gelsolin in the hippocampus and cortex of the brain in AD Tg mice as compared to vehicle-treated mice. TSA also increased the levels of γ-secretase and β-secretase activity in the brain. However, TSA did not show any effect on the activities or the expression levels of NEP and IDE in the brain. Furthermore, TSA treatment of AD Tg mice showed no change in the amyloid load (percent of examined area occupied by amyloid plaques) in the hippocampus and cortex, suggesting that TSA treatment did not result in the reduction of amyloid load. Interestingly, TSA prevented the formation of new amyloid deposits but increased the size of existing plaques. TSA treatment did not cause any apoptosis in the brain. These results suggest that TSA increases gelsolin expression in the brain, but the pleiotropic effects of TSA negate the anti-amyloidogenic effect of gelsolin in AD Tg mice.
Export Options
About this article
Cite this article as:
Wenzhong Yang, Abha Chauhan, Jerzy Wegiel, Izabela Kuchna, Feng Gu and Chauhan Ved, Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107125531
DOI https://dx.doi.org/10.2174/1567205011666141107125531 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Editorial (Thematic Issue : Recent Advances in Cancer Research: Targets and New Ligands)
Current Pharmaceutical Design Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Functional Imaging Combined with Multi-Detector CT: A Radionuclide Imaging Perspective
Current Medical Imaging NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry High-dose Vitamin D Supplementation on Type 1 Diabetes Mellitus Patients: Is there an Improvement in Glycemic Control?
Current Diabetes Reviews Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Disorders of Mechanisms of Calcium Metabolism Control as Potential Risk Factors of Prostate Cancer
Current Medicinal Chemistry Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Critical Aspects to be Considered Prior to Large-Scale Production of Peptides
Current Protein & Peptide Science Molecular Mechanisms Underlying the Dedifferentiation Process of Isolated Hepatocytes and Their Cultures
Current Drug Metabolism P2X Receptors and Inflammation
Current Medicinal Chemistry Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Diagnostic Reference Levels in Computed Tomography
Current Medical Imaging